1. Differences in children and adolescents with SARS-CoV-2 infection: a cohort study in a Brazilian tertiary referral hospital.
- Author
-
Marques HHS, Pereira MFB, Santos ACD, Fink TT, Paula CSY, Litvinov N, Schvartsman C, Delgado AF, Gibelli MABC, Carvalho WB, Odone Filho V, Tannuri U, Carneiro-Sampaio M, Grisi S, Duarte AJDS, Antonangelo L, Francisco RPV, Okay TS, Batisttella LR, Carvalho CRR, Brentani AVM, Silva CA, Eisencraft AP, Rossi Junior A, Fante AL, Cora AP, Reis AGAC, Ferrer APS, Andrade APM, Watanabe A, Gonçalves AMF, Waetge ARP, Silva CA, Ceneviva C, Lazari CDS, Abellan DM, Santos EHD, Sabino EC, Bianchini FRM, Alcantara FFP, Ramos GF, Leal GN, Rodriguez IS, Pinho JRR, Carneiro JDA, Paz JA, Ferreira JC, Ferranti JF, Ferreira JOA, Framil JVS, Silva KRD, Kanunfre KA, Bastos KLM, Galleti KV, Cristofani LM, Suzuki L, Campos LMA, Perondi MBM, Diniz MFR, Fonseca MFM, Cordon MNA, Pissolato M, Peres MS, Garanito MP, Imamura M, Dorna MB, Luglio M, Rocha MC, Aikawa NE, Degaspare NV, Sakita NK, Udsen NL, Scudeller PG, Gaiolla PVV, Severini RDSG, Rodrigues RM, Toma RK, Paula RIC, Palmeira P, Forsait S, Farhat SCL, Sakano TMS, Koch VHK, and Cobello Junior V
- Subjects
- Adolescent, Child, Cohort Studies, Cross-Sectional Studies, Humans, Infant, Newborn, SARS-CoV-2, Systemic Inflammatory Response Syndrome, Tertiary Care Centers, COVID-19 complications
- Abstract
Objectives: To compare demographic/clinical/laboratory/treatments and outcomes among children and adolescents with laboratory-confirmed coronavirus disease 2019 (COVID-19)., Methods: This was a cross-sectional study that included patients diagnosed with pediatric COVID-19 (aged <18 years) between April 11, 2020 and April 22, 2021. During this period, 102/5,951 (1.7%) of all admissions occurred in neonates, children, and adolescents. Furthermore, 3,962 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection samples were processed in patients aged <18 years, and laboratory-confirmed COVID-19 occurred in 155 (4%) inpatients and outpatients. Six/155 pediatric patients were excluded from the study. Therefore, the final group included 149 children and adolescents (n=97 inpatients and 52 outpatients) with positive SARS-CoV-2 results., Results: The frequencies of sore throat, anosmia, dysgeusia, headache, myalgia, nausea, lymphopenia, pre-existing chronic conditions, immunosuppressive conditions, and autoimmune diseases were significantly reduced in children and adolescents (p<0.05). Likewise, the frequencies of enoxaparin use (p=0.037), current immunosuppressant use (p=0.008), vasoactive agents (p=0.045), arterial hypotension (p<0.001), and shock (p=0.024) were significantly lower in children than in adolescents. Logistic regression analysis showed that adolescents with laboratory-confirmed COVID-19 had increased odds ratios (ORs) for sore throat (OR 13.054; 95% confidence interval [CI] 2.750-61.977; p=0.001), nausea (OR 8.875; 95% CI 1.660-47.446; p=0.011), and lymphopenia (OR 3.575; 95% CI 1.355-9.430; p=0.010), but also had less hospitalizations (OR 0.355; 95% CI 0.138-0.916; p=0.032). The additional logistic regression analysis on patients with preexisting chronic conditions (n=108) showed that death as an outcome was significantly associated with pediatric severe acute respiratory syndrome (SARS) (OR 22.300; 95% CI 2.341-212.421; p=0.007) and multisystem inflammatory syndrome in children (MIS-C) (OR 11.261; 95% CI 1.189-106. 581; p=0.035)., Conclusions: Half of the laboratory-confirmed COVID-19 cases occurred in adolescents. Individuals belonging to this age group had an acute systemic involvement of SARS-CoV-2 infection. Pediatric SARS and MIS-C were the most important factors associated with the mortality rate in pediatric chronic conditions with COVID-19.
- Published
- 2021
- Full Text
- View/download PDF